TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0

TuHURA Biosciences, Inc./NV

Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.
Acquired VISTA-inhibiting mAb TBS-2025 via Kineta merger (June 2025); planning Phase 2 in mutNPM1 AML.
Deferred development of IFx-3.0 mRNA candidate pending IFx-2.0 Phase 3 data; resources shifted to TBS-2025.
Filed unaudited pro forma financials reflecting Kintara (Oct 2024) and Kineta (June 2025) mergers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.